AR092707A1 - Metodo de produccion de derivado de tienopirimidina - Google Patents

Metodo de produccion de derivado de tienopirimidina

Info

Publication number
AR092707A1
AR092707A1 ARP130103480A ARP130103480A AR092707A1 AR 092707 A1 AR092707 A1 AR 092707A1 AR P130103480 A ARP130103480 A AR P130103480A AR P130103480 A ARP130103480 A AR P130103480A AR 092707 A1 AR092707 A1 AR 092707A1
Authority
AR
Argentina
Prior art keywords
production method
tienopirimidine
derivative production
salts
methoxypyridazin
Prior art date
Application number
ARP130103480A
Other languages
English (en)
Spanish (es)
Inventor
Sasaki Tsuyoshi
Komura Fumiya
Fukuoka Koichiro
Miwa Kazuhiro
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR092707A1 publication Critical patent/AR092707A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
ARP130103480A 2012-09-28 2013-09-27 Metodo de produccion de derivado de tienopirimidina AR092707A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012217679 2012-09-28

Publications (1)

Publication Number Publication Date
AR092707A1 true AR092707A1 (es) 2015-04-29

Family

ID=49448235

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103480A AR092707A1 (es) 2012-09-28 2013-09-27 Metodo de produccion de derivado de tienopirimidina

Country Status (20)

Country Link
US (8) US9758528B2 (da)
EP (3) EP4119564A1 (da)
JP (1) JP6250564B2 (da)
CN (2) CN104703992B (da)
AR (1) AR092707A1 (da)
CA (1) CA2881132C (da)
CY (1) CY1121641T1 (da)
DK (2) DK2900675T3 (da)
ES (2) ES2913753T3 (da)
HR (2) HRP20220622T1 (da)
HU (2) HUE059077T2 (da)
LT (2) LT2900675T (da)
PL (2) PL2900675T3 (da)
PT (2) PT3415517T (da)
RS (2) RS58703B1 (da)
SI (2) SI3415517T1 (da)
TR (1) TR201906318T4 (da)
TW (3) TWI602819B (da)
UY (1) UY35058A (da)
WO (1) WO2014051164A2 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2900675T (lt) 2012-09-28 2019-05-27 Takeda Pharmaceutical Company Limited Tienopirimidino darinių gamybos būdas
DK3263110T3 (da) 2015-02-26 2023-07-31 Takeda Pharmaceuticals Co Tablet, som omfatter et methoxyurinstofderivat og mannitolpartikler
CN110312512B (zh) 2016-09-30 2023-05-09 梦欧文科学有限责任公司 用于治疗子宫肌瘤和子宫内膜异位症的方法
JP7062673B2 (ja) 2016-09-30 2022-05-06 ミオバント サイエンシズ ゲーエムベーハー 前立腺がんの治療
AU2017357332B2 (en) * 2016-11-14 2021-10-28 Jiangsu Hengrui Medicine Co., Ltd. Crystalline form of GnRH receptor antagonist and preparation method therefor
AU2018280742B2 (en) 2017-06-05 2023-12-21 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN107188855A (zh) * 2017-07-14 2017-09-22 常州工程职业技术学院 一种3‑氨基‑6甲氧基哒嗪的制备方法
US11306104B2 (en) 2018-03-14 2022-04-19 Teva Pharmaceuticals International Gmbh Solid state forms of Relugolix
EP3666776A1 (en) 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
WO2020230094A1 (en) * 2019-05-15 2020-11-19 Dr. Reddy’S Laboratories Limited Amorphous and crystalline forms of relugolix
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
US20220267347A1 (en) * 2019-07-29 2022-08-25 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidinedione compounds and uses thereof
JP2022542159A (ja) * 2019-08-02 2022-09-29 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 固体形態レルゴリクス(Relugolix)
CN112321602A (zh) * 2019-08-05 2021-02-05 苏州鹏旭医药科技有限公司 一种瑞卢戈利药物中间体的制备方法
CN112390812A (zh) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 瑞卢戈利化合物的晶型和无定型固体及其制备方法
WO2021031148A1 (zh) * 2019-08-21 2021-02-25 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
CN115279769A (zh) * 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
WO2021069700A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN112745304A (zh) * 2019-10-29 2021-05-04 上海度德医药科技有限公司 一种Relugolix的制备方法及中间体化合物
CN111423452B (zh) * 2020-03-26 2023-08-22 江西青峰药业有限公司 瑞卢戈利的中间体及其制备方法和应用
CN113444105A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种Relugolix的制备方法
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途
CN111574534B (zh) * 2020-05-25 2021-06-04 东莞市东阳光新药研发有限公司 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
EP4157227A1 (en) 2020-05-29 2023-04-05 Myovant Sciences GmbH Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
US11655256B1 (en) 2020-11-06 2023-05-23 Macfarlan Smith Limited Processes for making a solid-state form of relugolix
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
CN112552312B (zh) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CN114685468A (zh) * 2020-12-25 2022-07-01 成都硕德药业有限公司 用于治疗子宫肌瘤的药物的中间体化合物及其制备方法
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
CN114907370B (zh) 2021-02-10 2023-11-03 奥锐特药业(天津)有限公司 高纯度的噻吩并嘧啶化合物及其制备方法
CN115073491A (zh) * 2021-03-12 2022-09-20 上海医药工业研究院 一种瑞卢戈利中间体、其制备方法及其应用
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
CN115594688B (zh) * 2021-06-28 2023-11-17 成都倍特药业股份有限公司 瑞卢戈利中间体的制备方法
WO2023066941A1 (en) * 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN114230576A (zh) * 2021-12-21 2022-03-25 伊诺药物研究(南京)有限公司 一种瑞卢戈利的制备方法
WO2023119333A1 (en) * 2021-12-25 2023-06-29 Dr. Reddy’S Laboratories Limited Process for preparation of relugolix and its intermediates
CN114409629B (zh) * 2022-02-22 2023-12-29 浙江科聚生物医药有限公司 一种高纯度Relugolix关键中间体的制备方法及应用
CN114790189B (zh) * 2022-02-24 2023-06-09 海化生命(厦门)科技有限公司 瑞卢戈利中间体的制备方法
CN114755320A (zh) * 2022-03-17 2022-07-15 南京方生和医药科技有限公司 一种3-氨基-6-甲氧基哒嗪有关物质的检测方法
WO2023194924A1 (en) * 2022-04-08 2023-10-12 Glenmark Life Sciences Limited Process for preparation of relugolix
CN114621249B (zh) * 2022-04-27 2024-01-26 江苏慧聚药业股份有限公司 瑞卢戈利关键中间体的制备
WO2023214935A1 (en) * 2022-05-05 2023-11-09 Scinopharm Taiwan, Ltd. Process for preparing relugolix and intermediates thereof
CN115594689B (zh) * 2022-07-14 2024-03-19 江西同和药业股份有限公司 一种瑞卢戈利中间体、一种瑞卢戈利的合成方法
CN114989134B (zh) * 2022-07-14 2023-11-14 江西同和药业股份有限公司 一种噻吩类化合物及其制备方法与应用
CN115417883A (zh) * 2022-09-16 2022-12-02 浙江科聚生物医药有限公司 一种瑞卢戈利的晶型及其制备方法
WO2024069492A1 (en) 2022-09-29 2024-04-04 Macfarlan Smith Limited Processes for the preparation and manufacture of relugolix
CN115650950A (zh) * 2022-11-03 2023-01-31 江西同和药业股份有限公司 一种瑞卢戈利中间体及其制备方法以及一种酰胺缩合方法
CN115650965B (zh) * 2022-12-26 2023-03-31 南京威凯尔生物医药科技有限公司 一种瑞卢戈利关键中间体的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116436B1 (da) 1971-05-31 1976-05-24
EP0237289A3 (en) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
JP2859791B2 (ja) * 1992-01-31 1999-02-24 吉富製薬株式会社 4−ブロモメチルビフェニル化合物の製造法
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
JPH10298156A (ja) * 1997-04-28 1998-11-10 Nippon Nohyaku Co Ltd 置換ハロメチルフェニルカルバミド酸エステル類の製造方法
US6297379B1 (en) 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
TWI225863B (en) * 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
JP2001316391A (ja) * 2000-02-29 2001-11-13 Takeda Chem Ind Ltd チエノピリミジン誘導体の製造法
EP1266898A4 (en) * 2000-02-29 2003-05-21 Takeda Chemical Industries Ltd PROCESSES FOR PRODUCING THIENOPYRAMIDINE DERIVATIVES
GB2361917A (en) 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
JP2002068044A (ja) 2000-09-04 2002-03-08 Yamaha Motor Co Ltd 自動二輪車用ハンドルシート
JP2002088044A (ja) * 2000-09-14 2002-03-27 Sumitomo Seika Chem Co Ltd 4’−ブロモメチル−2−シアノビフェニルの製造方法
BR0212173A (pt) 2001-09-04 2004-07-20 Akzo Nobel Nv Derivado de tieno [2,3-d] pirimidina, composição farmacêutica, uso de compostos de tieno[2,3-d]pirimidina ou um sal ou solvato deste farmaceuticamente aceitáveis, e, método para tratamento de distúrbios de fertilidade em pacientes em necessidade do mesmo
EP1479684A4 (en) * 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
AU2003303269A1 (en) 2002-12-20 2004-07-14 Koninklijke Philips Electronics N.V. Enhancing video images depending on prior image enhancements
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
US7300935B2 (en) * 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
US7947691B2 (en) 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
AU2005298064A1 (en) 2004-10-25 2006-05-04 Nihon Nohyaku Co., Ltd. Herbicide compositions for upland farming and control method
KR20080041662A (ko) * 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
RS55433B1 (sr) * 2011-02-23 2017-04-28 Lupin Ltd Derivati heteroarila kao modulatori nachr alfa7
JP2012217679A (ja) 2011-04-11 2012-11-12 Okumura Yu-Ki Co Ltd パチンコ遊技機
LT2900675T (lt) 2012-09-28 2019-05-27 Takeda Pharmaceutical Company Limited Tienopirimidino darinių gamybos būdas
DK3263110T3 (da) 2015-02-26 2023-07-31 Takeda Pharmaceuticals Co Tablet, som omfatter et methoxyurinstofderivat og mannitolpartikler

Also Published As

Publication number Publication date
US20170210753A1 (en) 2017-07-27
TW201418262A (zh) 2014-05-16
EP3415517B1 (en) 2022-04-20
HUE059077T2 (hu) 2022-11-28
US20190055261A1 (en) 2019-02-21
CN104703992A (zh) 2015-06-10
EP2900675B1 (en) 2019-03-06
TWI602819B (zh) 2017-10-21
US20150266891A1 (en) 2015-09-24
UY35058A (es) 2014-04-30
US20180319816A1 (en) 2018-11-08
RS63199B1 (sr) 2022-06-30
CN109053766A (zh) 2018-12-21
US20230212184A1 (en) 2023-07-06
WO2014051164A2 (en) 2014-04-03
JP6250564B2 (ja) 2017-12-20
DK3415517T3 (da) 2022-05-30
US11795178B2 (en) 2023-10-24
EP3415517A1 (en) 2018-12-19
RS58703B1 (sr) 2019-06-28
TR201906318T4 (tr) 2019-05-21
US11731983B2 (en) 2023-08-22
US10150778B2 (en) 2018-12-11
EP4119564A1 (en) 2023-01-18
CY1121641T1 (el) 2020-07-31
CA2881132C (en) 2020-11-24
DK2900675T3 (da) 2019-06-03
ES2724206T3 (es) 2019-09-09
US10464945B2 (en) 2019-11-05
CN104703992B (zh) 2019-03-05
EP2900675A2 (en) 2015-08-05
PT2900675T (pt) 2019-05-28
SI3415517T1 (sl) 2022-06-30
CN109053766B (zh) 2021-06-22
HRP20190729T1 (hr) 2019-06-14
TW201906847A (zh) 2019-02-16
US9758528B2 (en) 2017-09-12
LT3415517T (lt) 2022-06-10
US20200361953A1 (en) 2020-11-19
US10544160B2 (en) 2020-01-28
LT2900675T (lt) 2019-05-27
US11053257B2 (en) 2021-07-06
HRP20220622T1 (hr) 2022-06-24
TW201808962A (zh) 2018-03-16
HUE044048T2 (hu) 2019-09-30
US20220135585A1 (en) 2022-05-05
JP2015532262A (ja) 2015-11-09
CN113372358A (zh) 2021-09-10
ES2913753T3 (es) 2022-06-06
TWI641611B (zh) 2018-11-21
PT3415517T (pt) 2022-05-13
PL3415517T3 (pl) 2022-07-04
US20220204525A1 (en) 2022-06-30
TWI663171B (zh) 2019-06-21
CA2881132A1 (en) 2014-04-03
SI2900675T1 (sl) 2019-06-28
WO2014051164A3 (en) 2014-05-22
PL2900675T3 (pl) 2019-08-30

Similar Documents

Publication Publication Date Title
AR092707A1 (es) Metodo de produccion de derivado de tienopirimidina
CY1125072T1 (el) Μεθοδοι και ενδιαμεσες ενωσεις για την παρασκευη αναστολεα jak
FR22C1006I2 (fr) Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak)
PH12019502072A1 (en) Sustained release dosage forms for a jak1 inhibitor
BRPI1012108A2 (pt) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrila como inibidores de jak
HK1202541A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors raf 2-, 6-[2,3-d]
IL236294A (en) 4– (Converted-Amino) –7 h– Pyrrolo [3–2, d] Pyrimidines as lrrk2 Inhibitors
MY175450A (en) 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
CL2014000534A1 (es) Procesos para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo y compuestos intermediarios, inhibidores de jak; y compuesto intermediario (3-fluoro-2-(trifluorometil)piridin-4-il)(1,4-dioxa-8-azaspiro[4,5]decan-8-il)metanona.
BR112013025792A2 (pt) Inibidores de quinase relacionada à pirrolo[2,3-d] pirimidina tropomisina
IL268690A (en) (4)- 1-(1-(S-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(1-methyl-H1-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridine-2 (H1)-Onat salts and their crystalline structures and pharmaceutical preparations containing them
HK1248699A1 (zh) 用於製備{1-(乙基磺酰基)-3-[4-(7h-吡咯並[2,3-d]嘧啶-4-基)-1h-吡唑-1-基]氮雜環丁烷-3-基}乙腈的方法和中間體
EP2878595A4 (en) PROCESS FOR PREPARATION OF 4- [5- (PYRIDIN-4-YL) -1H-1,2,4-TRIAZOL-3-YL-] PYRIDINE-2-CARBONITRILE AND INTERMEDIATE PRODUCTS THEREFOR
HK1218756A1 (zh) 用作激酶活性調節劑的 -咪唑- -基 哌啶- -基 嘧啶- -胺衍生物
DK2753306T3 (da) Faste doseringsformer af (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chlor-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat
HK1206337A1 (en) Crystalline forms of (s)-4-aminon-(1-(4-chlorophenyl)-3- hydroxypropyl)-1-(7h -pyrrolo[2, 3-d]pyrimidi n-4-yl) piperidine-4- carboxamide (s)-4--n-(1-(4-)-3-)-1-(7h-[23-d]-4-) -4-
GB201819040D0 (en) 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same
AR085743A1 (es) Preparacion solida
TH148782B (th) รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate)
TH1401007889A (th) 4-(ซับสทิทิวเทด-อะมิโน)-7H-พิร์โรโล[2,3-d]พิริมิดีนชนิดใหม่ในฐานะเป็นตัวยับยั้ง LRRK2
TH1501000274A (th) วิธีการผลิต 4-[5-(ไพริดิน-4-อิล)-1h-1,2,4-ไตรอะโซล-3-อิล]ไพริดีน-2-คาร์โบไนไตรล์ และสารมัธยันตร์ของสารดังกล่าว
RU2012103219A (ru) Способ формирования оптимальной структуры инвестиционного портфеля с использованием генетических алгоритмов

Legal Events

Date Code Title Description
FB Suspension of granting procedure